Cancer and electromagnetic radiation therapy: Quo Vadis?
نویسنده
چکیده
In oncology, treating cancer with a beam of photons is a well established therapeutic technique, developed over 100 years, and today over 50% of cancer patients will undergo traditional X-ray radiotherapy. However, ionizing radiation therapy is not the only option, as the high-energy photons delivering their cell-killing radiation energy into cancerous tumor can lead to significant damage to healthy tissues surrounding the tumor, located throughout the beam's path. Therefore, in nowadays, advances in ionizing radiation therapy are competitive to non-ionizing ones, as for example the laser light based therapy, resulting in a synergism that has revolutionized medicine. The use of non-invasive or minimally invasive (e.g. through flexible endoscopes) therapeutic procedures in the management of patients represents a very interesting treatment option. Moreover, as the major breakthrough in cancer management is the individualized patient treatment, new biophotonic techniques, e.g. photo-activated drug carriers, help the improvement of treatment efficacy and/or normal tissue toxicity. Additionally, recent studies support that laser technology progresses could revolutionize cancer proton therapy, by reducing the cost of the needed installations. The aim of this review is to present some laser-based future objectives for cancer radiation therapy, aiming to address the relevant advances in the ionizing and non-ionizing radiation therapy, i.e. protons and heavy ions therapy, as well as photodynamic targeted and molecular therapies.
منابع مشابه
Metformin and cancer: Quo vadis et cui bono?
How many lives have already been saved by the anti-cancer drug metformin? Inadvertently perhaps, among the millions of type 2 diabetics with occult or known cancers and who have been prescribed metformin since the 1950s, thousands may have benefited from the anticancer properties of this first-line pharmacotherapy. Quo vadis? Now, researchers aim to move metformin from a non-targeted stage of c...
متن کاملDevelopment of Antibody‐Directed Therapies: Quo Vadis?
Less is more: The efficacy of antibody-drug conjugates (ADCs) for cancer therapy is traditionally associated with cleavable linkers for payload release. Evidence now suggests that simpler constructs without cleavable moieties can afford more stable and effective ADCs.
متن کاملQuo Vadis - Adaptive Heuristics for Routing in Large Communication Networks
This paper presents Quo Vadis, an evolving framework for intelligent tra c management in very large communication networks. Quo Vadis is designed to exploit topological properties of large networks as well as their spatio-temporal dynamics to optimize multiple performance criteria through cooperation among nodes in the network. It employs a distributed representation of network state informatio...
متن کاملQuo Vadis - A Framework for Intelligent Routing in Large Communication Networks
This paper presents Quo Vadis, an evolving framework for intelligent tra c management in very large communication networks. Quo Vadis is designed to exploit topological properties of large networks as well as their spatio-temporal dynamics to optimize multiple performance criteria through cooperation among nodes in the network. It employs a distributed representation of network state informatio...
متن کامل